Après 10 ans, le fonds Clinatec lance une nouvelle collecte de 30 millions d’euros d’ici 2030, pour attirer de nouveaux mécènes.
Faced with rapidly growing brain diseases (Parkinson’s, Alzheimer’s, epilepsy, head injuries, sleep disorders, etc.) and disabilities linked to spinal cord injuries (tetraplegia, paraplegia), this campaign aims to increase Clinatec’s capacity to rapidly offer patients promising non-drug therapeutic innovations. These therapies use technologies based on the modalities and principles of physics as well as artificial intelligence, focusing on infrared light, electricity, refrigeration and the analysis of brain signals.
The Fund’s pro bono chair, Sophie Cluzel, looks back on its successes and unveils its future objectives.
